Harmony Biosciences Announces FDA Approval Of WAKIX(R) (Pitolisant), A First-In-Class Medication For The Treatment Of Excessive Daytime Sleepiness In Adult Patients With Narcolepsy

WAKIX represents the first and only non-scheduled treatment approved for patients with narcolepsy in the U.S. PLYMOUTH MEETING, Pa., Aug. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Harmony Biosciences, LLC (Harmony) announced today that the ... Biopharmaceuticals, FDA Harmony Biosciences, WAKIX, pitolisant, excessive daytime sleepiness, narcolepsy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news